- Home
- CANF vs LMFA Comparison
CANF vs LMFA Comparison
Compare CANF & LMFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LMFA
- Stock Information
- Founded
- CANF 1994
- LMFA 2008
- Country
- CANF Israel
- LMFA United States
- Employees
- CANF N/A
- LMFA N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LMFA Finance: Consumer Services
- Sector
- CANF Health Care
- LMFA Finance
- Exchange
- CANF Nasdaq
- LMFA Nasdaq
- Market Cap
- CANF 9.4M
- LMFA 9.2M
- IPO Year
- CANF N/A
- LMFA 2015
- Fundamental
- Price
- CANF $1.54
- LMFA $1.97
- Analyst Decision
- CANF Strong Buy
- LMFA Hold
- Analyst Count
- CANF 2
- LMFA 1
- Target Price
- CANF $14.00
- LMFA N/A
- AVG Volume (30 Days)
- CANF 117.2K
- LMFA 81.8K
- Earning Date
- CANF 02-03-2025
- LMFA 11-13-2024
- Dividend Yield
- CANF N/A
- LMFA N/A
- EPS Growth
- CANF N/A
- LMFA N/A
- EPS
- CANF N/A
- LMFA N/A
- Revenue
- CANF $667,000.00
- LMFA $12,838,084.00
- Revenue This Year
- CANF $409.56
- LMFA N/A
- Revenue Next Year
- CANF N/A
- LMFA N/A
- P/E Ratio
- CANF N/A
- LMFA N/A
- Revenue Growth
- CANF N/A
- LMFA 27.81
- 52 Week Low
- CANF $1.29
- LMFA $1.84
- 52 Week High
- CANF $4.69
- LMFA $6.11
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- LMFA 37.40
- Support Level
- CANF $1.55
- LMFA $1.84
- Resistance Level
- CANF $1.64
- LMFA $2.37
- Average True Range (ATR)
- CANF 0.10
- LMFA 0.19
- MACD
- CANF 0.01
- LMFA 0.00
- Stochastic Oscillator
- CANF 11.76
- LMFA 18.31
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.